Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
Most coronary artery bypass graft surgery (CABG) patients develop high blood sugar while they
are in the hospital. No studies have shown what the best insulin regimen is for CABG patients
with type 2 diabetes is after going home from the hospital. Patients with high blood sugar
and diabetes after cardiac bypass surgery will be followed for 3 months to look at how well
their treatment(s) for diabetes work after discharge. Patients with diabetes will be
discharged on oral antidiabetic drugs or with insulin glargine injections based on their
sugar control. Patients with admission HbA1c < 7% (a laboratory value that shows the average
blood sugar level in the body over 3 months) will be discharged on the same diabetes
medications that they used before coming to the hospital. Those with an HbA1c between 7% and
9% will be discharged on insulin glargine at 50%-80% of the dose used in the hospital and
oral antidiabetic drugs. Those with an HbA1c > 9% will be discharged on glargine at 80-100%
of the dose used in the hospital in addition to oral antidiabetic drugs or with insulin
glargine and insulin glulisine. The primary outcome will be a change in HbA1c at 4 and 12
weeks after discharge.